Three-year estimate for Zika vaccine is 'optimistic,' admits WHO

10 March 2016

The claim by a Brazilian expert that a vaccine for the Zika virus could be three years away is ‘optimistic,’ according to the World Health Organization (WHO).

By that time, people in the currently affected Latin American regions are likely to have built up an immunity to the virus, but the WHO adds that there would still be a need to develop a vaccine for children and tourists, and in case an outbreak occurs elsewhere.

The comments come after a three-day summit on Zika research and development, convened by the WHO, which led international experts to agree on top priorities to fight the virus.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK